Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

October 23, 2026

Performance

52-Week Range 54.1% below 52-week high

39.78

40.2652W Low 86.7452W High

1 Week 13.2% below 1-week high

40.261W Low 45.841W High

Ionis Pharmaceuticals, Inc. - Common Stock (IONS) traded between $40.26 and $86.74 over the past 52 weeks and last traded at $39.78, 54.1% below its 52-week high. Over the past week it ranged between $40.26 and $45.84.

Past 12 Months

-11.4%

-8.6%

-27.8%

-47.1%

-50.1%

-46.0%

1W -$5.12

1M -$3.72

3M -$15.29

6M -$35.47

YTD -$39.89

1Y -$33.87

IONS was -46.0% over the past year, -47.1% over six months, -50.1% year to date, -11.4% in the last week.

12 Months vs Market

IONS

-46.0%

DIA

+12.0%

SPY

+12.0%

QQQ

+10.8%

IWM

+15.0%

Over the past 12 months IONS returned -46.0% versus DIA (Dow) +12.0%, SPY (S&P 500) +12.0%, QQQ (Nasdaq 100) +10.8% and IWM (Russell 2000) +15.0%.

Volume & Liquidity 0.24× 3-mo avg

Today 766,519 3-mo avg 3.2M

2.3M

2.8M

3.2M

3.0M

YTD

2.7M

2.6M

IONS most recently traded 766,519 shares against a 3-month average daily volume of 3.2M.

More News

Ionis ranked #1 on Science’s Top Employers list

October 22, 2026

Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? ↗

October 21, 2026

Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)

October 20, 2026

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)

October 16, 2026

Alnylam vs. Ionis: Here's the Better Bad-News Buy ↗

October 10, 2026

18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗

September 28, 2026

Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)

September 23, 2026

Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS

September 22, 2026

Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook ↗

September 20, 2026

Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock. ↗

Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks ↗

September 19, 2026

Via MarketBeat

September 14, 2026

Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making. ↗

September 09, 2026

Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Stay updated with the stocks that are on the move in today's after-hours session. ↗

September 04, 2026

Via Chartmill

September 04, 2026

ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients

Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment ↗

September 04, 2026

Via MarketBeat

September 03, 2026

Ionis to present at upcoming investor conferences

September 03, 2026

Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone ↗

September 03, 2026

Breakfast News: A Conversation With Ionis CEO ↗

August 22, 2026

Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026

August 20, 2026

Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗

August 16, 2026

Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock? ↗

August 14, 2026

IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law

August 08, 2026

From Schall, Brown & Schwartz LLP